"Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and over $10 billion in the first half of 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S ( NYSE: NVO). This Scandinavian economic behemoth is one of the highest-valued companies in Europe at over $500 billion, which exceeds Denmark's entire gross domestic product."
"Ironically, Ozempic and Wegovy, like many of Novo Nordisk's other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended side effect. Founded a century ago, Copenhagen-based Nordisk originally made insulin. After coming to the United States in 1982, it underwent several corporate changes until becoming Novo Nordisk in 1989. In addition to diabetes drugs, the company also makes drug treatments for wound healing, menopausal hormone replacement, and human growth hormone."
Ozempic generated about $17 billion in sales in 2024 and over $10 billion in the first half of 2025. Novo Nordisk's market value exceeds $500 billion, surpassing Denmark's entire GDP. Ozempic and Wegovy were developed for diabetes treatment; their weight-loss effects became lucrative unintended benefits. Novo Nordisk originated as Nordisk a century ago and evolved into Novo Nordisk after U.S. expansion and corporate changes by 1989. The company develops treatments beyond diabetes, including wound healing, menopausal hormone replacement, and human growth hormone. The obesity pipeline includes amycretin (FDA phase 1) and CagriSema (phase 2), alongside a promising oral weight-loss pill and corporate restructuring. The company projects the obesity drug market could reach $100 billion by 2030, elevating long-term investor focus on future performance.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]